# Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

> **NCT07376889** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Intermountain Health Care, Inc.** · enrollment: 2096 (estimated)

## Conditions studied

- Staphylococcus Aureus Bacteremia

## Interventions

- **DRUG:** Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)
- **DRUG:** Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
- **DRUG:** Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)
- **DRUG:** Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)

## Key facts

- **NCT ID:** NCT07376889
- **Lead sponsor:** Intermountain Health Care, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2029-01
- **Final completion:** 2029-01
- **Target enrollment:** 2096 (ESTIMATED)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07376889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07376889, "Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07376889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*